Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Philip Bonomi and Mary Jo Fidler.
Philip Bonomi
Connection Strength
3.694
Mary Jo Fidler
  1. Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer. Anticancer Res. 2012 May; 32(5):1705-10.
    View in: PubMed
    Score: 0.418
  2. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Ther Adv Med Oncol. 2012 Mar; 4(2):51-60.
    View in: PubMed
    Score: 0.414
  3. PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy. Br J Cancer. 2011 Dec 06; 105(12):1920-6.
    View in: PubMed
    Score: 0.405
  4. Treatment of locally advanced non-small cell lung cancer. Clin Adv Hematol Oncol. 2009 Jul; 7(7):455-64, 479-80.
    View in: PubMed
    Score: 0.344
  5. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94.
    View in: PubMed
    Score: 0.315
  6. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy. Cancers (Basel). 2021 Mar 20; 13(6).
    View in: PubMed
    Score: 0.194
  7. Theoretical and Practical Implications of Treating Cachexia in Advanced Lung Cancer Patients. Cancers (Basel). 2019 Oct 23; 11(11).
    View in: PubMed
    Score: 0.176
  8. Prognostic Significance of Skeletal Muscle Loss During Early Postoperative Period in Elderly Patients with Esophageal Cancer. Ann Surg Oncol. 2019 Nov; 26(12):3807-3808.
    View in: PubMed
    Score: 0.174
  9. The serum-based VeriStrat? test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients. BMC Cancer. 2018 03 20; 18(1):310.
    View in: PubMed
    Score: 0.157
  10. Differential expression of circulating biomarkers of tumor phenotype and outcomes in previously treated non-small cell lung cancer patients receiving erlotinib vs. cytotoxic chemotherapy. Oncotarget. 2017 Aug 29; 8(35):58108-58121.
    View in: PubMed
    Score: 0.148
  11. Practical and theoretical implications of weight gain in advanced non-small cell lung cancer patients. Ann Transl Med. 2017 Mar; 5(6):152.
    View in: PubMed
    Score: 0.146
  12. Treatment of advanced squamous cell carcinoma of the lung: a review. Transl Lung Cancer Res. 2015 Oct; 4(5):524-32.
    View in: PubMed
    Score: 0.133
  13. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):370-5.
    View in: PubMed
    Score: 0.109
  14. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol. 2011 Jun; 6(6):1079-86.
    View in: PubMed
    Score: 0.098
  15. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2010 Oct; 10(10):1589-99.
    View in: PubMed
    Score: 0.094
  16. Four-Phase, Definitive Chemoradiation for a Real-World (Poor Risk and/or Elderly) Patient Population With Locally Advanced Non-small Cell Lung Cancer. Cureus. 2022 Sep; 14(9):e29423.
    View in: PubMed
    Score: 0.054
  17. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition. J Immunol Methods. 2021 03; 490:112956.
    View in: PubMed
    Score: 0.048
  18. Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). J Thorac Oncol. 2018 09; 13(9):1393-1399.
    View in: PubMed
    Score: 0.040
  19. Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer. Am J Clin Oncol. 2015 Dec; 38(6):605-9.
    View in: PubMed
    Score: 0.034
  20. Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0-2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response. J Thorac Oncol. 2015 Oct; 10(10):1475-80.
    View in: PubMed
    Score: 0.033
  21. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care. 2016 May; 33(4):374-80.
    View in: PubMed
    Score: 0.032
  22. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 2014; 1(8):522-528.
    View in: PubMed
    Score: 0.031
  23. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy. Pract Radiat Oncol. 2014 Sep-Oct; 4(5):342-348.
    View in: PubMed
    Score: 0.029
  24. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):985-91.
    View in: PubMed
    Score: 0.023
  25. Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer. 2011 Feb; 71(2):186-90.
    View in: PubMed
    Score: 0.023
  26. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.